Read on Twitter
My top 10 learning points from the #ESCCongressA thread for cardiologists/general physicians
1) Post acute MI, transfuse if ≤8g/dL
Evidence: REALITY trial- not yet published – summary reported https://www.acc.org/latest-in-cardiology/clinical-trials/2020/08/29/13/09/reality
1/n
2) SGLT2i in addition to standard HF treatment significantly 
CV death, including in non-diabetic pts
Evidence: EMPEROR-Reduced ( https://www.nejm.org/doi/full/10.1056/NEJMoa2022190)
& metanalysis of DAPA-HF and EMPEROR-Reduced ( https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31824-9/fulltext)
#ESCCongress
2/n
CV death, including in non-diabetic pts Evidence: EMPEROR-Reduced ( https://www.nejm.org/doi/full/10.1056/NEJMoa2022190)
& metanalysis of DAPA-HF and EMPEROR-Reduced ( https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31824-9/fulltext)
#ESCCongress
2/n
3) Colchicine 0.5mg od in pts with chronic coronary diseaseCV death/MI/CVA
Evidence: LoDoCo 2 - https://www.nejm.org/doi/full/10.1056/NEJMoa2021372
#ESCCongress
3/n
CV death/MI/CVAEvidence: LoDoCo 2 - https://www.nejm.org/doi/full/10.1056/NEJMoa2021372
#ESCCongress
3/n
4) Dapagliflozin in pts with CKD, with or without T2DM, significantly risk of kidney failure, CV death and HF hospitalisation
Evidence: DAPA CKD – not yet published - https://www.escardio.org/The-ESC/Press-Office/Press-releases/DAPA
#ESCCongress
4/n
risk of kidney failure, CV death and HF hospitalisationEvidence: DAPA CKD – not yet published - https://www.escardio.org/The-ESC/Press-Office/Press-releases/DAPA
#ESCCongress
4/n
5) Digoxin could be considered as a first-line approach for rate control in older adults with AF
Evidence: RATE-AF – not yet published - https://cardiacrhythmnews.com/esc-2020-congress-digoxin-found-to-be-favourable-in-rate-control-for-permanent-af-patients/
#ESCCongress
5/n
Evidence: RATE-AF – not yet published - https://cardiacrhythmnews.com/esc-2020-congress-digoxin-found-to-be-favourable-in-rate-control-for-permanent-af-patients/
#ESCCongress
5/n
6) There is a new treatment option for HOCM – mavacamten
Evidence: EXPLORER-HCM - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31792-X/fulltext
#ESCCongress
6/n
Evidence: EXPLORER-HCM - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31792-X/fulltext
#ESCCongress
6/n
7) No need to stop ACEi/ARB in COVID pts
Evidence: BRACE CORONA - not yet published - https://www.escardio.org/The-ESC/Press-Office/Press-releases/LOPES
#ESCCongress
7/n
Evidence: BRACE CORONA - not yet published - https://www.escardio.org/The-ESC/Press-Office/Press-releases/LOPES
#ESCCongress
7/n
8) Early rhythm control decreases risk of adverse cardiovascular outcomes in AF
Evidence: EAST AFNET 4 https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
#ESCCongress
8/n
Evidence: EAST AFNET 4 https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
#ESCCongress
8/n
9)Post TAVI, aspirin alone is a better strategy than aspirin and clopidogrel
Evidence: POPULAR TAVI https://www.nejm.org/doi/full/10.1056/NEJMoa2017815
#ESCCongress
9/n
Evidence: POPULAR TAVI https://www.nejm.org/doi/full/10.1056/NEJMoa2017815
#ESCCongress
9/n
10) Either the sPESI or the HESTIA score can be used to identify ~ a third of pts with PE who can be discharged early and treated at home
Evidence: HOME PE - not yet published - https://www.escardio.org/The-ESC/Press-Office/Press-releases/Trial-clarifies-which-patients-with-acute-pulmonary-embolism-can-be-managed-at-home
#ESCCongress
10/10
Evidence: HOME PE - not yet published - https://www.escardio.org/The-ESC/Press-Office/Press-releases/Trial-clarifies-which-patients-with-acute-pulmonary-embolism-can-be-managed-at-home
#ESCCongress
10/10
